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Latent TB infection 
Mycobacterium tuberculosis 
a b s t r a c t 
Background: Interferon gamma release assays (IGRAs) are used to detect latent Mycobacterium tubercu- 
losis ( M.tb ) infection (LTBI) in adults, but their performance in older people is not well-established. We 
evaluated IGRAs for LTBI detection in older Hispanic recent TB contacts (ReC) or community controls 
(CoC). 
Methods: Cross-sectional assessment of LTBI with T-SPOT.TB and/or QuantiFERON-Gold in-tube or –Plus 
assay in older ( ≥60 years) and adult (18–50 years) Hispanic people. 
Results: We enrolled 193 CoC (119 adults, 74 older persons) and 459 ReC (361 adults, 98 older persons). 
LTBI positivity increased with age in CoC (19%–59%, P < 0.001), but was similar in ReC (59%–69%, P = 0.329). 
Older people had lower concordance between IGRAs (kappa 0.465 vs 0.688 in adults) and more incon- 
clusive results (indeterminate/borderline 11.6% vs 5.8% in adults, P = 0.012). With simultaneous IGRAs, in- 
conclusive results were resolved as positive or negative with the other IGRA. The magnitude of response 
to M.tb peptides in IGRAs was similar among age groups, but responsiveness to mitogens was lower in 
older people. 
Conclusions: IGRAs are suitable for LTBI detection in older people. Discordant and inconclusive findings 
are more prevalent in older people, but results are resolved when IGRA is repeated with a different IGRA 
test. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious 
Diseases. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
INTRODUCTION 
Mycobacterium tuberculosis ( M.tb ) infected nearly 10 million 
people and caused 1.8 million tuberculosis (TB) deaths worldwide 
Abbreviations: IGRAs, Interferon gamma release assays; LTBI, latent Mycobac- 
terium tuberculosis infection; TB, tuberculosis; ReC, recent TB contacts; CoC, com- 
munity controls; QFT, QuantiFERON; TST, tuberculin skin test. 
∗∗ Corresponding author: Dr. Blanca I. Restrepo, 1214 W Schunior, UTRGV-Edinburg 
Campus, Edinburg, TX, USA 
E-mail address: Blanca.i.restrepo@uth.tmc.edu (B.I. Restrepo). 
∗ Deceased 
in 2020. ( World-Health-Organization 2020 ) An estimated one- 
quarter of the world’s population has a latent Mycobacterium tuber- 
culosis ( M.tb ) infection (LTBI), with 5%–10% anticipated to develop 
TB disease over their lifetime. ( Houben and Dodd, 2016 ) Older peo- 
ple have a 1.5-fold risk of progressing to TB when compared with 
adults, and are prone to poor treatment outcomes with 20%–30% 
mortality. ( Hochberg and Horsburgh, 2013 , Abdelbary et al., 2017 , 
Garcia-Goez et al., 2020 ) TB risk factors in older people include 
a higher prevalence of LTBI and a dysfunctional immune system 
marked by inflammaging and oxidative stress. ( Hochberg and Hors- 
burgh, 2013 , Piergallini and Turner, 2018 ) Higher LTBI prevalence in 
https://doi.org/10.1016/j.ijid.2021.08.014 
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND 
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older people is largely attributed to their lifetime-accumulated risk 
of exposure to M.tb . ( Dutt and Stead, 1993 ) 
LTBI detection is based on immunological memory to M.tb pep- 
tides, measured using the tuberculin skin test (TST) in vivo or 
interferon gamma release assays (IGRAs) ex vivo. The TST de- 
tects recall immunity to intradermal M.tb purified protein deriva- 
tive antigens. ( Vukmanovic-Stejic et al., 2006 ) IGRAs are based 
on interferon(IFN)- γ production by peripheral blood mononu- 
clear cells (PBMCs) in response to specific M.tb peptides. ( T- 
SPOT.TB Package insert 2017 , QuantiFERON-TB Gold (QFT) ELISA 
Package Insert 2016 , QuantiFERON-TB Gold 2006 ) 
Interpretation of TST and IGRAs has been challenging in older 
people due to several factors. First, TST sensitivity is reported 
to decrease with older age ( Dorken et al., 1987 ) with higher 
false-negatives likely due to reduced skin immunity with aging. 
( Agius et al., 2009 , Zevallos and Justman, 2003 ) Second, LTBI is 
highly heterogeneous in older people due to a range of recent or 
remote exposures to pulmonary TB patients. Third, studies com- 
paring the performance of TST vs IGRAs (T-SPOT.TB vs QuantiF- 
ERONs) show conflicting results, with most reporting lower sensi- 
tivity of the TST, and among IGRAs a higher sensitivity of the T- 
SPOT.TB vs QuantiFERONs. ( Ferrara et al., 2009 , Bae et al., 2016 , 
Kobashi et al., 2009 ) When using active TB as a gold standard, 
most studies report lower sensitivity in older people with all as- 
says. However, these studies are limited by their focus on hospital- 
ized and severely ill patients (Bae et al., 2016, Kobashi et al., 2009 , 
Kwon et al., 2015 , Jeon et al., 2013 ), their use of QuantiFERON kit 
versions that are no longer commercially available, and their tar- 
geting of older Asian patients without data from Hispanic patients. 
To assess the performance of IGRAs for LTBI detection in older 
Hispanic people, we conducted a cross-sectional study comparing 
T-SPOT.TB and QuantiFERONs. We enrolled older people commu- 
nity controls or contacts of recent TB patients, with similar groups 
of younger adults as reference. Our findings indicated a higher pro- 
portion of discordant, borderline or indeterminate findings in older 
people, but these inconclusive results were always resolved as pos- 
itive or negative with the other IGRA. LTBI prevalence was similar 
with both IGRAs, and increased with age in the community con- 
trols, suggesting that IGRAs are suitable for assessing LTBI in older 
people. We provide further insight into the clinical interpretation 
of a positive IGRA in older people. 
METHODS 
Participant enrollment 
We enrolled adults (18–50 years) and older people ( > 60 years) 
in south Texas and northeastern Mexico between 2017 and 2021, 
consisting of an extended participant cohort recently described. 
( Scordo et al., 2021 ) The cohort included: 1) individuals attending 
pulmonary clinics due to recent exposure to newly diagnosed TB 
patients for at least 5 hours within 6 months of enrollment (re- 
cent contacts; ReC); and 2) a convenience sample of community 
controls (CoC) with no reported exposure or a remote history of 
exposure ( > 6 months before enrollment) to a TB case. In addition, 
we enrolled individuals 51–59 years old, with the same enrollment 
and classification criteria as those mentioned for ReC or CoC. This 
study was approved by human subjects institutional review boards 
in Mexico (110/2018/CEI) and the United States (HSC-SPH-19-0308), 
and all participants signed written informed consent. 
IGRAs 
Blood was collected at the time of enrollment and simultane- 
ously evaluated for LTBI with T-SPOT.TB (Oxford Immunotec) and a 
QuantiFERON test (Qiagen, Germantown). T-SPOT.TB evaluates the 
IFN- γ response of blood CD4 T-cell lymphocytes to M.tb antigens 
ESAT-6 (panel A) or CFP-10 (Panel B), while the QFT-GIT eval- 
uates these responses to the M.tb antigens ESAT-6, CFP-10, and 
TB7.7 (TB1). ( QuantiFERON-TB Gold 2006 ) The QFT-Plus contains a 
second tube with M.tb peptides that stimulate CD8 T-cells (TB2). 
( QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert 2020 ) Dur- 
ing this study, Qiagen transitioned from the QuantiFERON Gold In- 
tube (QFT-GIT) to QFT-Plus (collectively referred to as QFT), with 
most participants tested with the QFT-Plus version (399 of 524 par- 
ticipants, 76.1%). We did not find differences in their performance 
(Figure S1). Per manufacturer instructions, QFTs with low mitogen 
responses or high backgrounds were categorized as indeterminate 
( QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert 2020 ) and T- 
SPOT.TBs with 5–7 spots after subtraction of the negative control 
from the highest of panels A or B were categorized as borderline. 
( T-SPOT.TB Package insert 2017 ) When there was a borderline re- 
sult with T-SPOT.TB or an indeterminate with QFT (i.e., inconclu- 
sive results), the positive or negative result with the other IGRA 
determined the final LTBI diagnosis. 
Data analysis 
Data were analyzed using SAS v 9.4 (Cary, North Carolina). Chi- 
square or Fisher’s exact tests were used to compare categorical 
variables. Median values were compared with the Wilcoxon rank 
sum test. Comparisons of medians between more than 2 study 
groups were established by the Kruskal-Wallis test with the post 
hoc Dwass, Steel, Critchlow-Fligner method. The Cochran-Armitage 
trend test was used to assess significant changes over different age 
groups. Cohen’s kappa coefficient (k) was used to measure overall 
agreement between paired test results. ( McHugh, 2012 ) P values 
were considered significant if ≤0.05 and borderline significant if 
< 0.10. Graphs were plotted using GraphPad PRISM v 9.0. 
RESULTS 
IGRA prevalence across age groups 
We enrolled 652 participants: 193 CoC (119 adults; 74 older 
people) and 459 ReC (361 adults; 98 older people), with sociode- 
mographic and clinical characteristics similar to a subset of this 
cohort recently described (Table S1). ( Scordo et al., 2021 ) CoC 
differed from ReC in their higher level of education ( P = 0.001), 
prevalence of macrovascular disease ( P < 0.001) and total choles- 
terol levels ( P = 0.038; Table S1). LTBI prevalence was significantly 
higher among older people vs adults in the CoC group (56.7% in 
older people vs 23.2% in adults; P < 0.001), but similar between 
age groups of ReC (older people 71.3% vs adults 64.1%; P = 0.233; 
Table 1 ). We found several host characteristics associated with LTBI 
by univariate analysis, including hyperglycemia ( P = 0.045) and dia- 
betes ( P = 0.063) in adults, and lower education level ( P = 0.013) and 
macrovascular disease ( P = 0.080) in older people ( Table 1 ). By mul- 
tivariable analysis, hyperglycemia or diabetes were no longer as- 
sociated. LTBI was independently associated with lower education 
among all study participants (adjusted odds ratio (adj-OR) 1.71; 
95% CI 1.55, 2.53), or with macrovascular disease among LTBI older 
people in the ReC group (adj-OR 2.14, 95% CI 1.11, 4.12; Table S2). 
( Scordo et al., 2021 ) 
Next, we evaluated how LTBI prevalence changes with increas- 
ing age in CoC vs ReC groups by 10-year age intervals. For this 
analysis, we also included CoC and ReC 51–59 years old (n = 111; 
Supplemental material). Results are shown for when both IGRAs 
are completed in Fig. 1 (T-SPOT.TB and QFT) or for the T-SPOT.TB 
and QFTs alone in Figure S2. IGRA positivity increased with older 
age among CoC ( P < 0.001) but remained consistently higher than 
60% throughout all the studied ages in the ReC group ( P = 0.329). 
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Table 1 
LTBI test results among older people and young adults, by exposure history 
Community + Recent contacts Community Recent contacts 
Young adults Elderly Young adults Elderly Young adults Elderly 
n (%) n (%) P value n (%) n (%) P value n (%) n (%) P value 
Conclusive (T-SPOT.TB and QFT complement) a 0.075 < 0.001 0.641 
Negative 219 (45.6) 65 (37.8) 92 (77.3) 33 (44.6) 127 (35.2) 32 (32.7) 
Positive 261 (54.4) 107 (62.2) 27 (22.7) 41 (55.4) 234 (64.8) 66 (67.4) 
T-SPOT.TB 0.264 0.002 0.124 
Negative 230 (48.0) 72 (42.9) 92 (77.3) 37 (52.9) 138 (38.3) 35 (35.7) 
Positive 230 (48.0) 85 (50.6) 25 (21.0) 32 (45.7) 205 (56.9) 53 (54.1) 
Borderline 19 (4.0) 11 (6.6) 2 (1.7) 1 (1.4) 17 (4.7) 10 (10.2) 
QFT (QFT-Gold In-tube or QFT-Plus) 0.117 < 0.001 0.177 
Negative 173 (46.0) 58 (39.5) 58 (85.3) 30 (53.6) 115 (37.3) 28 (30.8) 
Positive 194 (51.6) 81 (55.1) 10 (14.7) 24 (42.9) 184 (59.7) 57 (62.6) 
Indeterminate 9 (2.4) 8 (5.4) 0 (0.0) 2 (3.6) 9 (2.9) 6 (6.6) 
Inconclusive (borderline or indeterminate) vs conclusive (positive and negative combined) b 
Borderline or indeterminate 28 (5.8) 20 (11.6) 0.012 2 (1.7) 3 (4.0) 0.313 26 (7.2) 17 (17.3) 0.002 
Borderline 19 (4.0) 11 (6.6) 0.171 2 (1.7) 1 (1.4) 0.893 17 (4.7) 10 (10.2) 0.041 
Indeterminate 9 (2.4) 8 (5.4) 0.077 0 (0.0) 2 (3.6) 0.116 9 (2.9) 6 (6.6) 0.106 
a LTBI was positive when the T-SPOT.TB or QuantiFERON (QFT) assays (Gold In-tube or QuantiFERON-Plus) were positive. Borderline or indeterminate results were com- 
plemented with the positive or negative finding from the other IGRA. 
b Comparisons of negative and positive values combined (conclusive) vs borderline or indeterminate or both types of inconclusive results combined. Differences between 
groups established by Chi-square test. Significant or borderline significant differences are shown in bold text. 
Fig. 1. Changes in the prevalence of IGRA-positive results across age groups. The 
prevalence of LTBI was based on a positive T-SPOT.TB or QuantiFERON assay (QFT- 
GIT or QFT-Plus). The prevalence of LTBI increased with age among the CoC 
( P = < 0.001) but not for ReC ( P = 0.354). LTBI was significantly higher among CoC vs 
ReC until aged 59 (non-overlapping 95% CIs) but not among those aged ≥60 years. 
The proportion of newly-infected individuals in the ReC groups was calculated by 
subtracting LTBI-positives from the baseline CoC group (line with triangles). 
CoC, Community controls; ReC, Recent contacts; LTBI, latent M. tuberculosis infec- 
tion. Vertical bars, 95% CIs for LTBI prevalence. IGRA, Interferon-gamma release as- 
say; QFT, QuantiFERON-Gold In-Tube and -Plus 
Our results also indicated that the proportion of new M.tb infec- 
tions among ReC was significantly higher in adults (mean 39.2%, 
95% CIs 29.6%, 48.8%) compared with older people (mean 11.4%, 
95% CI 5.2, 17.6%; P < 0.050; Fig. 1 ). In summary, IGRA positivity in- 
creased with age in older age CoC but remained consistently higher 
throughout all the age groups in the ReC. 
Concordance between IGRA assays 
The proportion of older people who tested IGRA positive was 
similar for T-SPOT.TB and QFT assays: 45.7% vs 42.9% in the CoC 
group and 54.1% vs 62.6% in the ReC group ( Table 1 ). Among par- 
ticipants tested simultaneously with both types of IGRA (518 of 
652 participants, 79.4%) in both the CoC and ReC groups, the over- 
all concordance between IGRAs was 80.4% (kappa 0.694, moder- 
ate; Fig. 2 ; Table S3). However, agreement between IGRAs differed 
by age group. Among all older people, the concordance was 71.4% 
Fig. 2. Concordance between IGRA assays, by age and study groups. The percentage 
of positive and negative agreement was estimated for participants in whom both 
types of IGRA assays were carried out simultaneously (n = 518 of 652, 79.4%) by age 
and study group. The sample size and kappa statistic (k) is provided for each study 
group. 
CoC, Community controls; ReC, Recent contacts.IGRA, Interferon-gamma release as- 
say 
(kappa 0.478, weak) vs 83.8% in adults (kappa 0.695, moderate). 
When age groups were further stratified by CoC or ReC, IGRAs 
from older people had a lower concordance compared with adults 
(CoC kappa: 0.342 vs 0.719 in adults; ReC kappa: 0.532 vs 0.660 in 
adults; Fig. 2 ; Table S3). Agreement was lower for the CoC vs ReC, 
and particularly low in older people (CoC: 65.4.2%, kappa 0.342, 
minimal; ReC: 74.8%, kappa 0.532, weak). In summary, the pro- 
portion of discordant results was highest among older people, and 
particularly in the CoC group (34.6%, Fig. 2 ). 
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Fig. 3. Resolution of inconclusive IGRAs. A. Among all study participants, borderline T- SPOT.TB was positive in 50% (14 of 28) of the cases by QFT, while indeterminate QFTs 
were positive by T- SPOT.TB in 100% (17 of 17) of the cases. B. Among all older participants, borderline T- SPOT.TB was positive in 64% (7 of 11) of the cases by QFT, while 
indeterminate QFTs were positive by T- SPOT.TB in 100% (8 of 8) of the cases. 
To determine the contribution of inconclusive results (indeter- 
minate with QFTs or borderline with T-SPOT.TB) to the discordance 
between IGRAs, we excluded participants with inconclusive results 
and re-evaluated the data. The concordance between IGRAs im- 
proved in nearly all study groups (Table S3). Among all partici- 
pants, the agreement improved by 7.5% (from 80.4% to 87.9% after 
exclusions). The largest improvement was among older ReC (from 
74.4% to 89.2%), the study group with the highest risk of TB. 
Interpretation of inconclusive results 
Given the contribution of borderline or indeterminate results to 
the discordance between IGRAs, we expanded these analyses. Par- 
ticipants with borderline T-SPOT.TB results (n = 28 of 30) and inde- 
terminate QFT results (n = 17 of 17) were tested with both IGRAs si- 
multaneously. In all cases, the other IGRA resolved the inconclusive 
findings, with all participants having a defined final classification 
of positive or negative LTBI (upper panel of Table 1 ). In compari- 
son, if only one IGRA were performed per participant, older people 
would have had a higher proportion of borderline results with the 
T-SPOT.TB (6.6% vs 4.0%) or indeterminate results with the QFTs 
when compared with adults (5.4% vs 2.4%; Table 1 ). When com- 
bining both types of observations, these inconclusive results (bor- 
derline + indeterminate results) were significantly higher among 
older ReC (17.3% vs 7.2% adults; P = 0.002), and there was a similar 
trend for the smaller CoC group (older people 4.0% vs 1.7% adults; 
P = 0.179; Table 1 ). Thus, older individuals had a higher likelihood 
of an inconclusive LTBI result than adults. 
We next determined if inconclusive results were more likely to 
be resolved as positive or negative with the complementary IGRA 
( Fig. 3 A-B). We found that a borderline T-SPOT.TB result was re- 
solved as positive with the QFT in at least half the cases (14 of 
28, 50% in adults; 7 of 11, 63.6% in older people; Fig. 3 ). In con- 
trast, an indeterminate result by QFT was resolved as positive with 
the T-SPOT.TB in 100% of the cases: 17 of 17 participants tested, in- 
cluding 8 of 8 older people. In all cases, indeterminate results were 
due to high IFN- γ background. In summary, borderline T-SPOT.TB 
results were true borderline, while indeterminate QFT results were 
always positive with the T-SPOT.TB. 
IFN- γ response among LTBI participants 
We evaluated differences in the magnitude of response to M.tb 
antigens (number of IFN- γ positive lymphocytes by T-SPOT.TB, or 
IFN- γ titers by QFT-Plus) by age group. Since the proportion of 
IGRA-positives was higher in older people, the analysis was lim- 
ited to those positive with any assay. In the CoC group, there were 
no differences in the magnitude of IGRA responses to M.tb anti- 
gens among age groups ( Table 2 ). In the ReC group, older people 
had fewer lymphocytes responses to the ESAT-6 antigen ( P = 0.05), 
but all other responses to M.tb antigens were similar among age 
groups. The only consistent difference in older people vs adults 
was their lower responsiveness to mitogens in the QFT-Plus assay 
in the CoC ( P = 0.064) and ReC ( P = 0.073). These findings were con- 
firmed when expanding our analyses to all study participants since 
the response to mitogens was not affected by the positivity of the 
IGRA (CoC P < 0.001; ReC P = 0.035). Finally, we found that regard- 
less of age, recent exposure to a TB patient (ReC group) was asso- 
ciated with higher IFN- γ secretion vs remote exposure (CoC group; 
Table S4). In summary, older age was associated with lower re- 
sponses to mitogens, while the timing since exposure to an active 
TB case influenced the magnitude of the response to M.tb antigens. 
DISCUSSION 
We evaluated the performance of IGRAs among Hispanic older 
people vs adults in ReC and CoC groups. This design allowed us to 
compare the performance of the T-SPOT.TB and QFT assays across 
age groups, and among participants, with recent vs remote expo- 
sure to active TB cases. Our design contrasts with most previous 
studies, where IGRAs were evaluated among active TB cases across 
age groups, or as part of outbreak investigations among older peo- 
ple. ( Ferrara et al., 2009 , Bae et al., 2016 , Kobashi et al., 2009 ) 
Furthermore, our analysis was done with QFT-Plus, in contrast to 
previous studies that evaluated earlier versions of QFT. ( Bae et al., 
2016 , Kobashi et al., 2009 , Xin et al., 2019 ) 
There is a concern that the decline in the strength of the 
immune response in older people may decrease the sensitivity 
of assays to detect LTBI in this population. ( Byng-Maddick and 
Noursadeghi, 2016 ) This limitation is observed for the TST 
( Dorken et al., 1987 , Kobashi et al., 2009 ), with a higher propor- 
tion of false negatives attributed to compromised skin immunity 
in older people. ( Agius et al., 2009 ) A lower sensitivity has also 
been reported for IGRAs in older people, although less marked 
than with the TST. However, these observations are from studies 
conducted amongst active TB patients, and with false-negatives as- 
sociated with very advanced TB disease, lymphopenia or malnu- 
trition. ( Bae et al., 2016 , Kobashi et al., 2009 , Tebruegge et al., 
2014 ) Evaluation of IGRAs in older people with TB in these studies 
may differ from results we obtained in those without TB for sev- 
eral reasons. First, our older participants did not have severe un- 
derlying conditions that could compromise their immunity, other 
than a high prevalence of diabetes that was not associated with 
their LTBI status (Table S2). Second, previous studies in participants 
with TB also reported higher indeterminate results in older people, 
but these were due to low mitogen responses ( Jeon et al., 2013 , 
Tebruegge et al., 2014 ), while our indeterminate results were due 
to high IFN- γ background. Third, we observed an increasing preva- 
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Table 2 
Magnitude of IGRA responses among participants positive for LTBI a , b 
Community Recent contacts 
Adults Elderly Adults Elderly 
n Median (IQR) n Median (IQR) P n Median (IQR) n Median (IQR) P 
T-SPOT.TB 
Nil 29 0 (0.0) 42 0 (1.0) 0.281 244 0 (1.0) 69 0 (0.0) 0.023 
ESAT6 - Nil 29 10 (21.0) 42 10.5 (17) 0.760 244 18 (19.0) 69 10 (17.0) 0.050 
CFP10 - Nil 29 16 (18.0) 42 20 (20) 0.767 244 22 (17.0) 69 22 (20.0) 0.998 
QFT-Plus 
Nil 14 0.2 (0.6) 31 0.2 (0.6) 0.787 139 0.4 (1.4) 44 0.5 (1.8) 0.764 
Mit-Nil 14 21.4 (16.0) 31 15.4 (15.5) 0.064 139 21.0 (11.6) 44 15.5 (15.5) 0.073 
TB1 - Nil 14 0.4 (10.2) 31 0.6 (1.8) 0.806 139 4.2 (6.6) 44 3.8 (6.5) 0.436 
TB2 - Nil 14 0.5 (8.2) 31 0.7 (2.5) 0.902 139 4.1 (7.1) 44 3.9 (6.5) 0.349 
Mit-Nil (all) c 53 25.6 (13.9) 56 15.5 (3.6) < 0.001 219 21.3 (11.5) 71 16.1 (14.4) 0.035 
a Participants with positive IGRAs included those with borderline or indeterminate results who were classified as positive based on the other IGRA assay 
b Values from the indeterminate reactions were excluded due to their high non-specific IFN- γ background; 
c Mitogen responses were also evaluated for all study participants, including those who tested IGRA-negative;Mit, mitogen; Group medians were compared 
by the Wilcoxon rank sum test; Statistically significant or borderline significant differences are in bold text. IGRA, Interferon-gamma release assay; QFT, Quan- 
tiFERON; Nil, negative control; IQR, interquartile range; All, indicates all participants analyzed 
lence of LTBI positives with age, even among individuals older than 
60 ( Fig. 1 ). However, we did not have a gold standard for TB in- 
fection since active TB patients were not studied, and hence, we 
cannot rule out a lower sensitivity of the IGRA assays in the old- 
est participants ( ≥70 years). We think lower sensitivity is unlikely 
because we did not detect a notable reduction in the magnitude 
of the cell-mediated immune responses to M.tb antigens in older 
people compared with adults ( Table 2 ), and the prevalence of LTBI 
was similar when using T-SPOT.TB vs QFTs (Figure S2C). Together, 
our results suggest that the sensitivity of IGRAs for the detection 
of LTBI cases is not significantly impacted by old age alone. 
Previous studies report challenges with IGRAs in older peo- 
ple vs adults, namely poorer concordance between IGRAs, or be- 
tween IGRAs and the TST. ( Ferrara et al., 2009 , Bae et al., 2016 , 
Kobashi et al., 2009 ) Studies have also reported a higher propor- 
tion of indeterminate results in older people. ( Kobashi et al., 2009 , 
Tebruegge et al., 2014 , Chee et al., 2008 , Kobashi et al., 2008 ) In 
our cohort, we also found that in older people vs adults, there 
was a lower concordance between IGRAs, and a higher propor- 
tion of indeterminate or borderline results. We found a relationship 
between both observations, with discordant results being largely 
attributed to inconclusive results. These unclear results hinder a 
physician’s ability to recommend LTBI treatment, in particular to 
older ReC who have a high risk of progression to active TB dis- 
ease, and in whom inconclusive results were the highest (17% of 
older ReC; Table 1 ). Importantly, in our cohort we found that the 
resolution of inconclusive results was possible in 100% of cases 
with a complementary IGRA, yielding a positive or negative re- 
sult in a timely manner. The resolution of inconclusive results led 
to improved concordance in all study groups, including in older 
ReC: from a kappa of 0.532 (weak) to 0.800 (strong) (Table S3). 
Thus, resolution of inconclusive results by testing with a second 
IGRA is a time-efficient alternative when compared with the rou- 
tine retesting of ReC 8–10 weeks later to confirm if there was a 
true conversion to a positive LTBI result. ( Mazurek et al., 2005 ) 
The higher risk of active TB development among older peo- 
ple has been largely attributed to their waning immune response. 
( Byng-Maddick and Noursadeghi, 2016 ) For decades, this hypothe- 
sis has been based in part on data showing the lower responsive- 
ness of older people to the TST. Our results using IGRAs do not pro- 
vide support for a marked immunocompromised response to M.tb 
antigens in older people. First, we confirmed that the prevalence of 
LTBI increases with age in the community, when using IGRAs that 
evaluate cell-mediated immunity to M.tb . Second, the magnitude of 
the response to M.tb antigens in the CoC or ReC group was compa- 
rable between older people and adults who were LTBI positive, and 
is consistent with a previous report. ( Tebruegge et al., 2014 ) Third, 
the higher proportion of indeterminate results with the QFT in 
older people was due to a high IFN- γ background in all cases, and 
not to low mitogen responses. Thus, higher indeterminate results 
in older people may be a reflection of their baseline inflamma- 
tory status (inflammaging) or immune hyper-responsiveness upon 
exposure to M.tb antigens. ( Piergallini and Turner, 2018 ) The lack 
of an evident compromise in T-cell responses to M.tb in older 
people is consistent with findings from a recent study by our 
group. ( Ault et al., 2018 ) Nevertheless, the lower responsiveness of 
older people to the T-cell mitogen in the QFT-Plus assay ( Table 2 ) 
suggests a generalized defect in cell-mediated immunity, consis- 
tent with their reduced responsiveness to vaccines. ( Abarca Tomas 
et al., 2013 ) 
The higher prevalence of LTBI in older people is thought to be a 
major contributing factor to their increased risk of active TB devel- 
opment. ( Hochberg and Horsburgh, 2013 , Horsburgh et al., 2010 ) 
However, in our cohort, the LTBI prevalence flattened at approx- 
imately 70%, with a significantly lower proportion of new infec- 
tions among older people vs adults ( Fig. 1 ). Thus, we posit that 
older individuals who are not markedly immunocompromised may 
have a higher resistance to LTBI conversion or active TB disease 
development compared with adults. There are several observations 
supporting this possibility. First, a recent historical review of the 
literature among individuals of all ages confirmed that active TB is 
more likely to develop shortly after initial infection, with a dwin- 
dling risk up to 2 years, and rarely thereafter. Although a case for 
older people is not explicitly made, a bimodal distribution for the 
risk of TB reactivation is not observed over time. ( Behr et al., 2018 ) 
Second, there are studies suggesting that LTBI-positive individu- 
als may be more protected from reinfection with M.tb . ( Dutt and 
Stead, 1993 , Andrews et al., 2012 ) Third, the interpretation of a 
positive LTBI result in individuals with remote exposure is unclear, 
with some having a robust recall response to a past LTBI but no 
longer harboring viable M.tb . ( Behr et al., 2018 ) Fourth, older peo- 
ple are more likely to have been exposed to M.tb during their 
lifetime, even multiple times, and hence, are a select groups of 
survivors of active TB and LTBI. ( Dutt and Stead, 1993 ) Thus, the 
higher prevalence of positive LTBI tests among older people as a 
group is not necessarily a risk factor for active TB disease devel- 
opment, except for individuals who still harbor dormant bacilli 
in granulomas and are immunocompromised. Further studies are 
needed to understand the relationship between a positive LTBI test 
result and the risk of progression to active TB disease, particularly 
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for older people with contacts from decades ago. These studies are 
critical to guide decisions on LTBI treatment in the older popula- 
tion. ( Zevallos and Justman, 2003 , Sterling et al., 2020 ) 
We recognize study limitations. First, there is no gold standard 
for LTBI assessment, so we based LTBI on positivity with any of the 
2 IGRAs tested. Second, we switched from the QFT-GIT to the QFT- 
PLUS kit version during the study; however, 76.1% of the partici- 
pants were evaluated with the -PLUS kit, and the performance of 
both kit versions was similar (Figure S1). The inclusion of both kits 
allowed for additional analyses in our cohort and, in our hands, the 
TB2 tube in the QFT-PLUS had a minor improvement in sensitivity 
( ∼2%; Table S4); this was expected given that the tube was added 
to improve sensitivity in TB patients. ( Petruccioli et al., 2016 ) Third, 
the cross-sectional nature of our design did not allow for the iden- 
tification of the subset of older participants with recent IGRA con- 
version who are thought to have the highest risk of progression 
to active TB disease. Fourth, comparison of new LTBI between ReC 
and CoC may be biased by sociodemographic differences that are 
associated with higher exposure to M.tb , such as lower education 
in the ReC (a proxy for socioeconomic status; Table S1). Finally, 
our study included older people with comorbidities such as dia- 
betes and macro- and micro-vascular diseases, but data cannot be 
extrapolated to those severely immunocompromised. 
Overall, our results suggest that IGRAs are not affected by wan- 
ing immunity in older people, which contrasts with previous stud- 
ies using the TST or studies in older people with active TB. Fur- 
thermore, despite a higher proportion of discordant or inconclusive 
results in older people vs adults, the resolution of inconclusive re- 
sults was always possible when using a complementary IGRA. This 
finding is not unexpected due to differences between IGRAs in the 
technique used (i.e., fixed number of PBMCs per reaction for the 
T-SPOT.TB vs fixed volume of blood with QFTs), and the under- 
lying biological difference between a borderline vs an indetermi- 
nate result. ( T-SPOT.TB Package insert 2017 , QuantiFERON-TB Gold 
Plus (QFT-Plus) Package Insert 2020 ) Thus, IGRAs are suitable to 
evaluate LTBI in older people. When results of an initial test are in- 
conclusive (borderline or indeterminate), we recommend a repeat 
test with the other IGRA, which will likely provide a conclusive re- 
sult. 
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